Gerresheimer AG: directors' dealings · Germany · BaFin

About Gerresheimer AG

Gerresheimer AG is a German industrial group focused on pharmaceutical packaging and drug-delivery systems. Listed on Xetra/Frankfurt (DAX/MDAX/SDAX), the company is based in Germany, in Düsseldorf. Its roots go back to 1864, when Ferdinand Heye founded a glassworks in Gerresheim near Düsseldorf. Over time, the business evolved from a traditional glassmaker into a global supplier of higher-value solutions for the pharmaceutical, biotech, healthcare and cosmetics industries. Today, Gerresheimer’s operating model is built around three main divisions: Plastics & Devices, Primary Packaging Glass and Advanced Technologies. The group develops and manufactures primary packaging and drug-delivery solutions designed to protect, store and simplify the administration of medicines. Its portfolio includes vials, ampoules, bottles, containers for solid and liquid medicines, closure systems, prefillable syringes, insulin pens, inhalers and connected devices. Gerresheimer also positions itself as a system and solution provider for more complex medicines, biologics and selected cosmetic applications, rather than merely a commodity packaging manufacturer. From a competitive perspective, Gerresheimer holds a strong position in pharmaceutical primary packaging, a market supported by long-term structural drivers such as aging populations, the growth of biopharmaceuticals and rising regulatory requirements around safety, quality and traceability. The company’s global industrial footprint is a key asset: it operates more than 40 production plants worldwide and follows a “local for local” manufacturing approach across Europe, the Americas and Asia. This helps the group serve multinational pharma customers close to end markets while reducing supply-chain risk. Recent developments have been significant. In fiscal 2024, Gerresheimer completed the acquisition of Bormioli Pharma in December 2024, broadening its product range and strengthening its closure-systems offering for pharma and biopharma customers. In 2025, the company announced an expansion of its Wertheim site in Germany, including a new facility for ready-to-fill vials aimed at sensitive biologics. More recently, on 10 February 2026, Gerresheimer said it was postponing publication of its 2025 annual and consolidated financial statements while internal investigations continued regarding revenue recognition and accounting practices for 2024 and 2025, and it also initiated the sale of Centor Inc. to optimize its capital and financing structure. For investors, Gerresheimer remains a structurally attractive healthcare packaging and devices story, but the latest governance and reporting developments warrant close monitoring.